Company Filing History:
2 out of 199 
2 out of 178 
Years Active: 2008-2013
Title: Il-Sang Cho: Innovator in ALK5 & ALK4 Inhibitors
Introduction
Il-Sang Cho is a notable inventor based in Seoul, South Korea. He has contributed significantly to the field of medicinal chemistry, particularly in the development of inhibitors targeting various signaling pathways associated with fibrosis. With two patents to his name, he stands out among contemporary innovators.
Latest Patents
Il-Sang Cho's recent innovations include two patents focused on 2-pyridyl substituted imidazoles. The first patent describes these compounds as ALK5 and/or ALK4 inhibitors, outlining a compound formula that is useful in treating renal, liver, or pulmonary fibrosis. The second patent similarly details compounds that inhibit the TGF-β and/or activin signaling pathway in mammals, indicating their potential application in therapeutic settings.
Career Highlights
Throughout his career, Il-Sang Cho has been affiliated with prominent organizations, including SK Chemicals Co., Ltd. and the Ewha University-Industry Collaboration Foundation. His expertise in the field of pharmaceuticals and biochemistry positions him as a valuable asset in the research and development sector.
Collaborations
Il-Sang Cho has worked closely with colleagues such as Dae-Kee Kim and Yung-Jue Bang, contributing to collaborative efforts in pushing the boundaries of innovation in his field. These partnerships have likely enhanced the depth and breadth of his research initiatives.
Conclusion
Il-Sang Cho exemplifies dedication and creativity in the pursuit of breakthroughs in medical treatment. His contributions, particularly in developing compounds that address significant health challenges, mark him as a prominent figure in the landscape of inventions and innovations. He continues to pave the way for research that may lead to improved therapies for fibrotic diseases.